Stallergenes gets European approval for dust mite allergy tablet

Stallergenes Greer, which is based in France, will compete with ALK within the indication.


ALK's archrival, Stallergenes Greer, is closing in on the lucrative allergy pill market, which ALK has called one of the most important future growth markets.

On Monday, Stallergenes revealed in a press release that it has obtained European approval for its dust mite allergy tablet Stagr320.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs